| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/27/2023 | 60.26% | Stifel | $10 → $7.5 | Maintains | Buy |
| 09/15/2023 | 498.29% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 08/22/2023 | 124.36% | Stifel | $9 → $10.5 | Maintains | Buy |
| 08/16/2023 | 124.36% | UBS | $2.5 → $10.5 | Upgrades | Neutral → Buy |
| 08/04/2023 | 498.29% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 07/07/2023 | 102.99% | Stifel | $9 → $9.5 | Maintains | Buy |
| 06/06/2023 | -35.9% | Piper Sandler | $2 → $3 | Maintains | Underweight |
| 04/27/2023 | 92.31% | Stifel | $10 → $9 | Maintains | Buy |
| 04/14/2023 | 113.68% | Stifel | $18 → $10 | Maintains | Buy |
| 04/13/2023 | -46.58% | Truist Securities | $5 → $2.5 | Maintains | Hold |
| 02/28/2023 | -35.9% | Piper Sandler | → $3 | Initiates Coverage On | → Underweight |
| 02/01/2023 | 6.84% | Truist Securities | $9 → $5 | Maintains | Hold |
| 12/14/2022 | -9.19% | UBS | → $4.25 | Initiates Coverage On | → Neutral |
| 08/09/2022 | 156.41% | Truist Securities | → $12 | Downgrades | Buy → Hold |
| 06/13/2022 | 476.92% | Credit Suisse | $35 → $27 | Maintains | Outperform |
| 08/23/2021 | 562.39% | Credit Suisse | $40 → $31 | Maintains | Outperform |
| 07/15/2021 | 434.19% | Evercore ISI Group | → $25 | Initiates Coverage On | → Outperform |
| 03/22/2021 | 647.86% | Credit Suisse | → $35 | Initiates Coverage On | → Outperform |
| 03/19/2021 | 647.86% | Truist Securities | → $35 | Initiates Coverage On | → Buy |
| 03/09/2021 | 434.19% | Stifel | → $25 | Initiates Coverage On | → Buy |
| 12/03/2020 | 113.68% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
What is the target price for Aemetis (AMTX)?
The latest price target for Aemetis (NASDAQ: AMTX) was reported by Stifel on November 27, 2023. The analyst firm set a price target for $7.50 expecting AMTX to rise to within 12 months (a possible 60.26% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aemetis (AMTX)?
The latest analyst rating for Aemetis (NASDAQ: AMTX) was provided by Stifel, and Aemetis maintained their buy rating.
When is the next analyst rating going to be posted or updated for Aemetis (AMTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aemetis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aemetis was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.
Is the Analyst Rating Aemetis (AMTX) correct?
While ratings are subjective and will change, the latest Aemetis (AMTX) rating was a maintained with a price target of $10.00 to $7.50. The current price Aemetis (AMTX) is trading at is $4.68, which is out of the analyst's predicted range.